Your new experience awaits. Try the new design now and help us make it even better

CORRECTION article

Front. Oncol., 01 August 2025

Sec. Breast Cancer

Volume 15 - 2025 | https://doi.org/10.3389/fonc.2025.1658958

Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial

This article is a correction to:

  1. Neoadjuvant chemotherapy with or without Metformin in early stage or locally advanced (nonmetastatic) triple negative breast cancer -An open label Phase 2 Randomized controlled trial

    1. Read original article
Vinod K. Ramani*&#x;Vinod K. Ramani1*†Ajaikumar Basavalinga SadashivaiahAjaikumar Basavalinga Sadashivaiah2Radheshyam NaikRadheshyam Naik3
  • 1Preventive Oncology, Healthcare Global, Bangalore, India
  • 2Radiation Oncology, Healthcare Global, Bangalore, India
  • 3Medical Oncology, Healthcare Global, Bangalore, India

A Correction on
Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial

By Ramani VK, Basavalinga Sadashivaiah A and Naik R (2025) Front. Oncol. 15:1561692. doi: 10.3389/fonc.2025.1561692

In the published article, there was an error in the affiliation of the first author. Instead of “Preventive Oncology, Sammprada Cancer Hospital, Bangalore, India”, it should be “Preventive Oncology, Healthcare Global, Bangalore, India”.

In the published article, there was an error in the affiliation of the third author. Instead of “Preventive Oncology, Sammprada Cancer Hospital, Bangalore, India”, it should be “Medical Oncology, Healthcare Global, Bangalore, India”.

The corresponding author email was erroneously given as:dmlub2RyYW1hbmk3N0BnbWFpbC5jb20=. The correct email address is:ZHJ2aW5vZC5yQGhjZ2VsLmNvbQ==.

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: metformin, survival analysis, triple negative breast neoplasm, remission, neoadjuvant

Citation: Ramani VK, Sadashivaiah AB and Naik R (2025) Correction: Neoadjuvant chemotherapy with or without metformin in early-stage or locally advanced (non-metastatic) triple negative breast cancer—an open-label phase 2 randomized controlled trial. Front. Oncol. 15:1658958. doi: 10.3389/fonc.2025.1658958

Received: 03 July 2025; Accepted: 07 July 2025;
Published: 01 August 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Ramani, Sadashivaiah and Naik. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Vinod K. Ramani, ZHJ2aW5vZC5yQGhjZ2VsLmNvbQ==

†ORCID: Vinod K. Ramani, orcid.org/0000-0002-6531-9579

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.